The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.
Topical finasteride can reduce scalp DHT as effectively as oral finasteride with fewer systemic effects, but availability is limited. Some users make their own solutions due to limited access.
A 26-year-old male is documenting his hair regrowth journey using 0.5mg dutasteride and 5mg oral minoxidil, transitioning from 5% topical minoxidil. He reports no significant side effects after one week, except for slight water retention and increased libido.
The user started using EssenGen 6-Plus, containing 6% minoxidil and 0.05% finasteride, along with 1% Nizoral shampoo, and reported noticeable hair growth in 7 weeks. They experienced some chest tightness but are monitoring it, and they are satisfied with the progress despite using a silicone-containing shampoo.
Someone switched from topical minoxidil to oral minoxidil and found it more effective and convenient, reporting improvements in hair, eyebrows, eyelashes, and beard without scalp issues. They are seeking long-term experiences from others who made the same switch.
Concerns about hair loss treatments like finasteride and minoxidil not being administered during a coma. Dutasteride remains in the system longer, and hair loss may not be immediate if treatment stops temporarily.
The conversation discusses the timing of applying Minoxidil and finasteride after microneedling. Opinions vary, with some suggesting immediate application and others recommending waiting to avoid skin irritation.
A user started taking finasteride 1mg/day for hair loss but hasn't seen results yet. They also take vitamins and asked about adding minoxidil and the effectiveness of LLLT.
A 23-year-old started using 0.5mg Dutasteride and 2.5mg Minoxidil daily for hair loss and is considering adding RU58841 or GHK-cu. Users suggest waiting a few months before adding anything and mention Koshine's kx-826 as a potentially better alternative to RU58841.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.
A user is considering dutasteride mesotherapy for hair loss due to concerns about oral side effects from high DHT levels. They have been using topical finasteride with minoxidil but are exploring mesotherapy as an alternative, while another user shares their experience with mesotherapy sessions using dutasteride and minoxidil without side effects.
Topical finasteride is considered safer for the liver than oral finasteride due to less systemic absorption, but regular liver function tests are advised. The user is concerned about liver health due to a history of NAFLD and is exploring topical finasteride as a safer alternative.
The conversation is about the legitimacy and affordability of ordering a Minoxidil response test from TrichoGene, an India-based company, as an alternative to Daniel Alain. The user is seeking feedback on whether TrichoGene is a reliable option.
The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.
Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.
A user started using topical finasteride, switching from 0.1 g to 0.2 g, and is concerned if this dosage is too high. They are seeking advice on the appropriate amount to apply.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
The user reported significant hair improvement over 15 months using dutasteride, minoxidil (oral and topical), RU58841, ketoconazole, and microneedling. They are considering a hair transplant in 4-6 months.
The conversation is about a user dealing with androgenetic alopecia using minoxidil 5% and attempting to import Adenogen tonic from Japan, which was rejected by Spanish customs. The user seeks advice on obtaining Adenogen or Adenovital within the EU or tips for passing customs.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
Apply tretinoin cream first, then minoxidil, as tretinoin can enhance minoxidil absorption. Allow some time between applications to avoid skin irritation.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
The user has been using oral Minoxidil, Finasteride, and Biotin for hair recovery and is considering adding topical Minoxidil and dermastamping to improve results. It is suggested to use micro-needling once a week with a 24-hour gap before applying topical Minoxidil.
User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
People discuss taking finasteride and dutasteride with various drinks, noting that water is common, while some avoid grapefruit juice. Opinions vary on whether the choice of beverage affects drug absorption.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
User plans to switch from oral to .005% topical finasteride, using a solvent from minoxidilmax and later Essengen-F. They will monitor DHT levels and seek advice on solvents and sleep caps.